SYNOPSIS A rise in blood pressure associated with oral contraceptives is well established but the frequency with which it develops is not known. Early results from a controlled long-term prospective study have shown no significant change in mean systolic or diastolic pressures or mean weight in 31 women after four months on oral contraceptives. In no individual subject was there a significant change in blood pressure or weight over the short period of the experiment.
SYNOPSIS A rise in blood pressure associated with oral contraceptives is well established but the frequency with which it develops is not known. Early results from a controlled long-term prospective study have shown no significant change in mean systolic or diastolic pressures or mean weight in 31 women after four months on oral contraceptives. In no individual subject was there a significant change in blood pressure or weight over the short period of the experiment.
In 10 women, oral contraceptives have been shown to induce a consistent rise in plasma renin substrate and cortisol concentrations after four weeks. At this time plasma renin concentration had fallen slightly in eight out of 10 women but neither plasma aldosterone nor plasma corticosterone showed any consistent response.
Raised blood pressure (above 140/90 mm Hg) associated with oral contraceptives has been reported on several occasions but the incidence of hypertension in women taking these drugs is not known. Changes in renin substrate, renin, and aldosterone secretion and excretion have also been observed, but no direct relationship between these factors and the rise in blood pressure has yet been established. This paper is arranged in two sections: a short review of blood pressure and endocrine changes during the administration of oral contraceptives followed by a preliminary report of a study of their effects on the plasma concentrations of renin, renin substrate, aldosterone, corticosterone, and cortisol.
Effect on Blood Pressure
A few single cases of hypertension have occurred in women taking oral contraceptive preparations (Brownrigg, 1962; Owen, 1966) and two reports describe hypertension, malignant in one case, developing during this treatment (Dussek, 1969; Harris, 1969 Weinberger, Dowdy, Nokes, and Luetscher (1968) .
In a retrospective study of the effects of oral contraceptives on the total population taking these compounds, Loudon and Burton (1969) analysed data of three years from 153 cases, and found a mean annual systolic increment of 1.8 mm Hg and a diastolic increment of 0.7 mm Hg, both greater than would be expected from the effects of aging alone. Goodlin and Waechter (1969) , in a retrospective review of 120 randomly selected women, concluded, however, that no consistent pattern was present over a similar period. A series of 496 contraceptive users were found to have significantly higher mean systolic and diastolic pressure levels than non-users after correction for age, height, weight, and arm circumference, but in a sample after a further year no change in blood pressure was found in either group (Kunin, McCormack, and Abernathy, 1969) .
A short prospective study of 43 women with diastolic pressures below 80 mm Hg taking Ovulen (ethynodiol diacetate: 1 mg, mestranol: 0.1 mg) was described by Tyson (1968) . Of these, six showed a rise in diastolic pressure to 90 mm Hg or more after one to four months of treatment, which was reversed in all six within 30 days of withdrawal of the drug. No abnormal blood pressure changes were found in 120 women of comparable age, followed simultaneously, using an intrauterine contraceptive device. This contrasts with the work of Chernick (1968) who found no statistically significant difference in the proportions of patients with raised blood pressure between a group of 303 women using Orthonovum (norethindrone: 5 mg, mestranol: 0 075 mg) and another of 56 women using an intrauterine contraceptive device for periods of up to the equivalent of 10 menstrual cycles.
In a larger prospective study over two years of some 9,000 patients taking oral contraceptives (Chiddell, 1969) 90 women had blood pressures over 140/90 mm Hg, 31 of whom had levels below this at their first visit to the clinic and 37 of whom were already taking oral contraceptives when the initial blood pressure readings were taken. Fifty per cent of those whose blood pressure was already high (>140/90 mm Hg) showed a further rise on taking the drug. When the drug was withdrawn, 84% of all the cases with high blood pressure showed an improvement in this measurement, while pressure remained high in 91 % of those cases where the treatment was continued.
One possible explanation of the hypertensive effects of oral contraceptive steroids may be an alteration in the activity of the renin-angiotensinaldosterone system. This is discussed in the next section.
Effects on Plasma Renin, Renin Substrate, Aldosterone, Corticosterone, and Cortisol
Renin released from the juxtaglomerular cells of the kidney reacts with an alpha-2-globulin fraction of plasma ('renin substrate') to form a decapeptide, angiotensin I, which is further split to an active octapeptide, angiotensin II, by a converting enzyme (Fig. 1) . Angiotensin II, which will now be referred to as 'angiotensin', may act on peripheral blood vessels as a vasopressor, directly on the kidney, and on the adrenal cortex to stimulate aldosterone secretion. Oral contraceptive therapy consistently leads to an increase in plasma renin substrate (Helmer and Judson, 1967; Laragh et al, 1967; Newton, Sealey, Ledingham, and Laragh, 1968; Skinner, Lumbers, and Symonds, 1969) . The maximum effect develops from four days to two weeks after starting treatment, and substrate concentrations return to normal two to four weeks after stopping the drug. Plasma renin activity is raised in the majority of subjects (Laragh et al, 1967; Weinberger et al, 1968; Crane and Harris, 1969) but plasma concentration of the enzyme is not increased, apparently irrespective of the brand of contraceptive compound used, and may even fall (Skinner et al, 1969) .
The stage of the menstrual cycle at which treatment commences appears to have no effect on the degree to which renin substrate increases, but rises in renin activity are most marked when the control samples are taken in the first half of the cycle when renin activity is at its lowest (Skinner et al, 1969) . Increased aldosterone secretion and excretion rate in subjects given oral contraceptives, and increased plasma protein binding of aldosterone have been described (Layne, Meyer, Vaishwanar, and Pincus, 1962; Laragh et al, 1967; Weinberger et al, 1968; Crane and Harris, 1969) Plasma cortisol concentration rises during oral contraceptive therapy (Layne et al, 1962; Burke, 1969; Damkjaer Nielsen, Binder, and Starup, 1969; O'Connell and Welsh, 1969) largely due to an increase in the level of the protein-bound component of the hormone, but as far as we are aware, plasma corticosterone concentration has not previously been measured in this situation.
There follows a preliminary report of a study set up to assess the frequency and degree of blood pressure elevation in a large group of women taking contraceptive tablets, and to examine some of the endocrine changes occurring in a much smaller group.
Methods BLOOD PRESSURE
Two brands of oral contraceptive have been chosen: Ovulen as a preparation thought to produce frequent sodium retention, and Norinyl-l (norethisterone: 1 mg, mestranol: 0.05 mg) as one likely to produce less sodium and water retention. Women wishing to use oral contraception are randomly allocated to one or other of these preparations. Women using a cervical cap or an intrauterine contraceptive device act as controls but are not randomly allocated to these methods. Only women who have not taken oral contraceptives for at least six months before the trial are admitted.
Previous medical history and general examination are conducted by the doctors of the Family Planning Association who also select the method of contraception to be used. The blood pressure and weight are recorded by one doctor who has no knowledge of the women's history, or of the contraceptive technique used. Blood pressure is taken in the sitting position using a standard sphygmomanometer cuff on the same arm at each visit. To reduce observer bias, the sphygmomanometer used is that devised by Rose, Holland, and Crowley (1964 (p < 0-001) in all 10 women studied ( Fig. 5) with levels up to four times those obtained before treatment. No difference was noted between the effects of the brands used. There was no change detectable in concentration over the period of the menstrual cycle.
Plasma renin concentration fell in eight of the 10 subjects (Fig. 6 ) but this was not statistically significant by Student's t test. Although the mean plasma concentrations of aldosterone and corticosterone were slightly higher after oral contraceptive administration, these changes also did not achieve statistical significance (Fig. 7) . Conversely, plasma cortisol concentration increased in every case, the mean plasma cortisol showing a significant increase (p < 0.01), but in all cases remained within normal limits (Fig. 7) although in the upper part of these.
Discussion CHANGES IN RENIN, RENIN SUBSTRATE, AND CORTICOSTEROIDS
These results agree with those of previous workers in that oral contraceptives induce a consistent rise in the plasma concentration of renin substrate (Helmer and Judson, 1967; Laragh et al, 1967; Skinner et al, 1969) and that plasma renin concentration was unchanged or decreased slightly (Skinner et al, 1969) . Giving oestrogen has long been known to increase the concentration of various plasma proteins and it is highly probable that it is this component rather than the progestogen which causes changes in plasma renin substrate. Helmer and Griffith (1952) found that rat plasma renin substrate was increased by oestrogen administration and an increase in aldosterone- Both subjects were symptom-free and no explanation of these high values can be given.) Fig. 7 Plasma steroid concentrations before and during oral contraception. (Duplicate samples from a large normal human plasma pool were used to determine the reproducibility of the technique of assay.) Treatment binding protein (Meyer, Layne, Tait, and Pincus, 1961; Layne et al, 1962) and cortisol-binding protein (Sandberg and Slaunwhite, 1959; Daughaday, Holloszy, and Mariz, 1961; Layne et al, 1962; Doe, Mellinger, Swaim, and Seal, 1967; Keane, Pearson, and Walker, 1969) have been reported in human subjects after similar treatment. These effects have been attributed to an increased hepatic synthesis induced by the steroid hormone. However, plasma renin substrate may increase in renal insufficiency and after bilateral nephrectomy (Cook and Lee, 1965; Laragh et al, 1967) and the possibility of renal involvement in the response of this globulin to oral contraceptives cannot therefore be ignored.
Progesterone may contribute to the increase in substrate (Newton et al, 1968) , and, as an aldosterone antagonist (Landau, Bergenstal, Lugibihl, and Kascht, 1955; Landau and Lugibihl, 1961) , may possibly also provoke an increase in aldosterone secretion in certain circumstances.
Progestogens with an alpha substitute at position C-17, however, may have the reverse effect on aldosterone secretion by promoting sodium retention (Landau, Lugibihl, and Dimick, 1958 (Woods, 1967; Laragh et al, 1967) , although Chiddell (1969) could not find any correlation between toxaemia in pregnancy and hypertension during oral contraception. Weight gain and fluid retention occur in some cases but were not a feature of the two hypertensive cases reported in this study.
It seems unlikely that the rise in blood pressure is associated with an increase in the sensitivity of vascular smooth muscle to the vasoconstrictor effects of angiotensin since sodium balance is not altered, and neither progesterone (Chesley and Tepper, 1967) nor an oestrogen-progesterone mixture (Woods, 1967) appears to alter the pressor response to angiotensin in rats.
Increased angiotensin levels may, in some circumstances, exert a direct inhibitory effect on renin activity (Genest, De Champlain, Veyrat, Boucher, Tremblay, Strong, Kiow, and Aurele, 1964; Vander and Geelhoed, 1965; Klaus and Heizmann, 1967 ). An impairment or failure of this feedback, such as has been postulated for subjects who develop hypertension during oral contraception (Newton et al, 1968; Skinner et al, 1969) , could result in a rise in blood pressure. However, there is no direct evidence for such a hypothesis.
Progesterone rabbits (Horrobin, 1968) . It is possible that the progestogen component of the oral contraceptive preparation may contribute to the development of hypertension in women, but this cannot account for the infrequency of such an occurrence. It is hoped that a long-term study, possibly augmented by an investigation of the separate effects of oestrogens and progestogens, may reveal more clearly the mechanism of blood pressure changes and its relationship, if any, to changes in the renin-angiotensin-aldosterone system. This study was supported by grants from the Council for the Investigation of Fertility Control, the James McCunn Trust, and the Medical Research Council.
